Risk and timing of clinical events according to diabetic status of patients treated with everolimus‐eluting bioresorbable vascular scaffolds versus everolimus‐eluting stent: 2‐year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 91, Iss. 3, 2018-02 ,pp. : 387-395

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical outcomes of overlapping versus non‐overlapping everolimus‐eluting absorb bioresorbable vascular scaffolds: An analysis from the multicentre prospective RAI registry (ClinicalTrials.gov identifier: NCT02298413)

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 91, Iss. 1, 2018-01 ,pp. : E1-E16

John Wiley & Sons Inc

Access to resources Recommend Favorite

The ABSORB bioresorbable vascular scaffold: A novel, fully resorbable drug‐eluting stent: Current concepts and overview of clinical evidence

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 1522-1946, Iss. 4, 2015-10 ,pp. : 664-677

John Wiley & Sons Inc

Access to resources Recommend Favorite

The ABSORB bioresorbable vascular scaffold: A novel, fully resorbable drug‐eluting stent: Current concepts and overview of clinical evidence

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 86, Iss. 4, 2015-10 ,pp. : 664-677

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anatomical features and management of bioresorbable vascular scaffolds failure: A case series from the GHOST registry

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 85, Iss. 7, 2015-06 ,pp. : 1150-1161

John Wiley & Sons Inc

Access to resources Recommend Favorite